Aileron Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

Aileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights

Aileron Therapeutics to Present at 2021 H.C. Wainwright Global Life Sciences Conference

Aileron Therapeutics Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Aileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering with Participation by New Fundamental Healthcare Investors Acorn Bioventures, BVF Partners, L.P. and Maven Investment Partners

Aileron Therapeutics Announces $35.9 Million Registered Direct Offering

Aileron Therapeutics Provides Business Update and Outlines 2021 Strategic Priorities

Aileron Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights

Aileron Therapeutics Announces Proof-of-Concept Clinical Data from Ongoing ALRN-6924 Phase 1b Trial Presented in Late-Breaking Presentation at the EORTC-NCI-AACR Annual Symposium

Aileron Therapeutics to Host Conference Call to Discuss Results from Phase 1b Proof-of-Concept Study of Chemoprotective Therapy ALRN-6924 Being Presented at EORTC-NCI-AACR Annual Symposium